Research Aims Sample Clauses

Research Aims. “Research Aims” shall have the meaning ascribed to such term in the CRADA, as summarized in Exhibit B of this Agreement.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Research Aims. In order to gain a full appreciation of next generation institutional transnationalism, the study explores the following. First it describes and analyses the patterns of next generation inclusion across a range of philanthropic and political transnational organizations. Second, it investigates the form, frequency and impact of next generation institutionalized activities. Third, the study examines the factors that contribute to the emergence of next generation institutionalized activities. Amongst these factors, particular attention is paid to human variables, opportunity structures, processes of socialization, and individual volition, and how next generation institutionalized transnationalism affects assimilation and incorporation within the United States. The research on these aspects of next generation transnationalism has been organized around five key aims. These are outlined below, and briefly positioned in relation to related works. Furthermore, some brief details are provided on how these aims are addressed. This chapter then outlines the structure of the thesis, before concluding with a brief section on important aspects of the terminology used in the study. Previous studies that have explored institutional (Xxxxx-Xxxxxx, 2005; Xxxxx and Xxxxxx, 2008) and non- institutional (Xxxxxx and Xxxxxx, 2002; Xxxxxxx, 2002; Xxxxxxxx et al., 2002) transnational activities among individuals born and/or raised in the United States predict mostly limited involvement - at rates that are significantly lower than the parental generation. This study therefore examines to what extent this also applies to their involvement in transnational organizations, paying particular attention to variations in an attempt to isolate factors and organizational characteristics that could explain next generation inclusion or exclusion. Itzigsohn and Xxxxxxx (2002) distinguished between ‘broad’ and ‘narrow’ forms of transnational activities: the former designated occasional practices and the latter more regular commitments. This study investigates the positions and responsibilities that next generation individuals have assumed within their respective organizations, and the impact their contributions have generated in order to consider to what extent their contributions conform to ‘broad’ or ‘narrow’ definitions of transnationalism.
Sample 1Sample 2
Research Aims. The objective of this study was to evaluate the effectiveness of CLTS in achieving and sustaining household ODF status in Bukwo, Uganda. The specific aims were: 1. To examine if CLTS is a culturally sensitive and respectful approach for hygiene and sanitation promotion in Bukwo, Uganda 2. Understand the motivators and barriers to achieving ODF status among the households triggered by CRS CLTS programming 3. Among households that attained ODF status, identify what motivates them to continue this practice. Among households that stopped open defecation post-CLTS triggering but have resumed the practice, explore reasons for barriers to latrine use.
Sample 1
Research Aims. To fill these research gaps, the present research uses secondary data analysis of two national datasets related to drug and MAT use: the National Surveys on Drug Use and Health and the Treatment Episodes Datasets. Use of nationally-representative data among adults and a specific focus on differences by opioid use type enable generalizable findings that forecast needs in order to strategically plan targeted prevention and treatment interventions. This dissertation research aims to: Aim 1: Describe current prevalence and temporal trends in opiate use in the US overall, by opiate use type (NMPO, heroin, and co-use) and demographic (sex, race, age, rurality), substance use and mental health characteristics. Aim 2: Explore associations between multilevel factors related to increased NMPO use (e.g. healthcare access, perceived risk, availability) and transition from NMPO to heroin co-use. Aim 3: Examine temporal trends in demographic characteristics of MAT admissions at publically-funded facilities in the US overall, and by opioid use type, demographic characteristics, and dimensions of healthcare access. Sub-aim 3a: Explore differences in MAT completion by opiate use type, demographic characteristics, and dimensions of healthcare access (i.e. health insurance coverage and referral by care provider).
Sample 1
Research Aims. In summary, the literature regarding the “gateway” phenomenon in the context of the current tobacco and marijuana market and social norms landscape is limited, with additional research needed to more fully characterize who is most likely to initiate use overall using distinct products and the subsequent use patterns that evolve based on which product was first used. This paper aims to contribute to the literature by examining tobacco and marijuana use outcomes (i.e., number of products ever used or currently used) in relation to first product used among ever users of tobacco or marijuana, as well as characterizing those who initially use the distinct tobacco products or marijuana.
Sample 1
Research Aims. All the work you do is headed towards publications in peer-reviewed journals and conferences. The number of publications expected depends on your situation. For example, if you are enrolled in a master’s thesis program, you can expect to publish 1 journal and 2 conference papers. If you are enrolled in a doctoral program, expect to have 3 journal papers and 6 conferences publications. Conferences could include SPIE Medical Imaging, ISBI, IPCAI & CARS, MICCAI, ICCR, MR in RT Symposium. If you are new to research, you need to realize that it is fundamentally different than academic assignments. Research involves developing novel knowledge. This means that it has never been done before and there is a risk of not meeting the objectives. Because this lab is concerned with ‘applying’ existing knowledge in Computer Science, that risk is reduced. Once meeting a “roadblock”, successful researchers will investigate the reasons behind it. You will need to be diligent, detail-oriented but also committed and perseverant. Once the cause(s) of the ‘roadblock’ is identified, you will be best placed to propose solutions and alternatives. Another key is communication. Communicating what you worked on, what you are working on, and any impediment is paramount. Dr. Xxxxx has an open-door policy, schedules frequent 1-on-1 meetings and we hold lab meetings to facilitate communication. As a member of the research team, you can expect to gain translational skills within several areas of Computer Science; you will be trained in image processing, best development practices and you will be provided with a unique opportunity to learn and revisit concepts learned in the classrooms. We work together to create a personalized and focused training plan for your professional insertion.
Sample 1
Research Aims. The aim of this study was to identify the genetic cause of NSC. Initially we planned to map areas of homozygosity within the genome of NSC patients by utilising SNP linkage analysis and homozygosity mapping with platforms such as HomozygosityMapper and BeadStudio. This was followed by WES analysis. Through the data generated, potential strong candidate genes were identified and prioritised based on their encoded proteins function and tissue distribution of expression, primarily in the liver and biliary tract. Subsequently, by direct sequencing of the genes, we aimed to confirm the disease causing mutations and the potential effect of the gene product in the manifestation of NSC.
Sample 1
AutoNDA by SimpleDocs
Research Aims. The IOM revised guidelines include a call for increased research surrounding GWG. AI/AN women are a unique population to the United States with high rates of maternal obesity and diabetes. There needs to be more research surrounding the effects of prepregnancy BMI and GWG during pregnancy and subsequent pregnancy outcomes to help guide clinical management of high-risk pregnancies among AI/AN women. The primary objective of this study is to investigate the individual and joint effects of high prepregnancy BMI and excess GWG on fetal macrosomia using a retrospective cohort study of AI/AN women. A sub-analysis of only non-diabetic women will be conducted to account for the possible confounding of diabetes. The secondary aim of this analysis is to display the associations of macrosomia with these two main exposures for each individual state to look at possible geographic differences.
Sample 1
Research Aims. ‌ The primary research questions that this paper will address are concurrent with those that shaped the research design for the Latrine Training Mat study (referred to in this paper as the WASH-LTM study). In order to ascertain whether the latrine training mat could be considered a feasible tool, it was necessary to first understand the context of rural Western Kenya and how it influences children’s defecation practices – particularly those that take place between the ages of two and five years old. It was hypothesized that, during this age range, children were developmentally capable of learning to use the latrine, but this learning process was often delayed due to specific contextual barriers. Consequently, this study aimed to first identify the local perceptions and practices that related to this issue, and then to evaluate how the latrine training mat could be used and would be perceived within the local context. The following are the three questions that shaped the LTM research design, and which will direct the discussion put forth in this paper. Chapter 2: Literature Review‌
Sample 1

Related to Research Aims

  • Technology Research Analyst Job# 1810 General Characteristics

  • Research Primary Investigator as part of a multi-site study (25 points) • Co-Investigator as part of a multi-site study (20 points) • Primary Investigator of a facility/unit based research study (15 points) • Co-Investigator of a facility/unit based research study (10 points) • Develops a unit specific research proposal (5 points) • Conducts a literature review as part of a research study (5 points)

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Research Funding (a) During each Collaboration Term and in connection with any wind-down activities contemplated by Section 13.4. Gilead shall reimburse Hookipa for all Out-of-Pocket Costs actually incurred (with no markup) by Hookipa in connection with the applicable Program, to the extent specifically contemplated in the applicable Research Plan and in accordance with the applicable Research Budget. Gilead shall reimburse the undisputed amount of such Out-of-Pocket Costs incurred in a [***] within [***] days after receipt from Hookipa of an invoice therefor issued within [***] days after the end of such [***]. (b) During each Collaboration Term for a Program, Gilead shall reimburse Hookipa at the FTE Rate for the costs of any FTEs (not to exceed the number of FTEs specified in the applicable Research Plan for such Program for any period without first obtaining, in each case, Gilead’s prior written consent) actually performing activities allocated to Hookipa under such Research Plan. Hookipa shall provide to Gilead, within [***] days after the end of each [***] during each Collaboration Term, a report indicating the number of FTEs actually provided by Hookipa with respect to each Program during such [***], Hookipa shall use standard industry systems and processes to record the number of hours and FTEs actually applied to each Program, which systems and processes shall be consistently and equitably applied to all Hookipa research programs with Third Parties. Gilead shall reimburse Hookipa the undisputed amount for such FTE costs incurred in a [***] within [***] days after receipt from Hookipa of an invoice therefor issued within [***] days after the end of each [***]. (c) For clarity, Gilead shall not be obligated to reimburse Hookipa for any costs or expenses incurred by Hookipa in the course of its activities under the Programs, other than: (i) those costs and expenses expressly identified in this Section 9.6 or elsewhere in this Agreement; (ii) reimbursement for the supply of Licensed Products to Gilead in accordance with the terms of any supply agreement entered into by the Parties pursuant to Section 7.2; or (iii) any other costs and expenses approved by Gilead in writing in advance.

  • Research Support (a) Having regard to the resources reasonably available for such purposes, the Operator will cooperate with AHS to provide such participation by its Staff as may be reasonable in relation to the carrying out of research within the Province. (b) The Operator agrees to promptly notify AHS in the event that it undertakes or agrees to participate in any form of clinical trial, research project, instrument use, or similar activity which in any way relates to the Services provided under this Agreement. The Operator shall, upon request, provide AHS with written evidence of Client disclosure and consent to research.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!